Shares of Ingevity Corporation (NYSE:NGVT – Get Free Report) have been given an average recommendation of “Hold” by the five analysts that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $80.00.
NGVT has been the subject of a number of recent research reports. Weiss Ratings upgraded Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, July 31st. Wall Street Zen downgraded shares of Ingevity from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 1st.
Get Our Latest Analysis on Ingevity
Insider Transactions at Ingevity
Institutional Investors Weigh In On Ingevity
Several large investors have recently added to or reduced their stakes in NGVT. BlackRock Inc. purchased a new stake in shares of Ingevity in the second quarter valued at approximately $400,545,000. California State Teachers Retirement System increased its position in Ingevity by 7,309.2% during the 2nd quarter. California State Teachers Retirement System now owns 3,003,451 shares of the company’s stock valued at $224,268,000 after purchasing an additional 2,962,914 shares during the period. Millennium Management LLC raised its holdings in shares of Ingevity by 1.3% in the 3rd quarter. Millennium Management LLC now owns 1,189,524 shares of the company’s stock valued at $65,650,000 after purchasing an additional 15,562 shares in the last quarter. Royce & Associates LP raised its stake in Ingevity by 7.7% in the fourth quarter. Royce & Associates LP now owns 1,111,158 shares of the company’s stock worth $65,758,000 after buying an additional 79,059 shares in the last quarter. Finally, Brown Advisory Inc. lifted its holdings in Ingevity by 15.4% during the fourth quarter. Brown Advisory Inc. now owns 1,040,944 shares of the company’s stock worth $61,603,000 after buying an additional 138,859 shares during the period. 91.59% of the stock is owned by institutional investors.
Ingevity Price Performance
Shares of NYSE:NGVT opened at $69.64 on Monday. Ingevity has a twelve month low of $45.85 and a twelve month high of $79.29. The stock’s 50 day moving average is $72.63 and its 200-day moving average is $71.44. The company has a quick ratio of 1.15, a current ratio of 1.61 and a debt-to-equity ratio of 22.52. The firm has a market capitalization of $2.39 billion, a price-to-earnings ratio of 47.38 and a beta of 1.17.
Ingevity (NYSE:NGVT – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $1.74 EPS for the quarter, topping the consensus estimate of $1.33 by $0.41. Ingevity had a return on equity of 284.70% and a net margin of 4.65%.The firm had revenue of $314.10 million during the quarter, compared to the consensus estimate of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. Sell-side analysts forecast that Ingevity will post 5.4 EPS for the current fiscal year.
Ingevity Company Profile
Ingevity Corporation (NYSE: NGVT) is a specialty chemicals and materials company that develops products designed to improve performance, sustainability and resource efficiency across a range of industrial and consumer applications. Its businesses serve automotive, infrastructure, industrial, agricultural and other end markets.
The company’s portfolio includes activated carbon products used in vehicle evaporative-emissions control systems, industrial air and water purification, and other filtration applications.
Recommended Stories
- Five stocks we like better than Ingevity
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.
